The revenue for the cell therapy Carvykti and the EGFR-targeted lung cancer duo Rybrevant-Lazcluze contributed to double digit gains in oncology drug sales.

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

The company hopes to commercialize its tumor profiling assay after it secures $10 million via a share purchase agreement.

Debiopharm will take over development of the PKMYT1 inhibitor and advance it in combination with its WEE1 inhibitor in the MYTHIC trial.

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.